The 7 major cystinosis markets reached a value of USD 198.8 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 324.9 Million by 2035, exhibiting a growth rate (CAGR) of 4.58% during 2025-2035.
Report Attribute
|
Key Statistics
|
---|---|
Base Year | 2024 |
Forecast Years | 2025-2035 |
Historical Years |
2019-2024
|
Market Size in 2024
|
USD 198.8 Million |
Market Forecast in 2035
|
USD 324.9 Million |
Market Growth Rate 2025-2035
|
4.58% |
The cystinosis market has been comprehensively analyzed in IMARC's new report titled "Cystinosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Cystinosis is a rare, multisystem hereditary illness characterized by the accumulation of cystine, an amino acid, in several human tissues and organs such as the kidneys, eyes, muscles, liver, pancreas, and brain. The kidneys and eyes are the two organs most damaged. Cystinosis is classified into three types: nephropathic cystinosis, intermediate cystinosis, and non-nephropathic (or ocular) cystinosis. The age of onset, symptoms, and severity of this ailment might vary widely from person to person. Some common indications of the disorder include excessive thirst, electrolyte imbalances, vomiting, dehydration, fever, growth delay, failure to thrive, scarred or cloudy corneas, light sensitivity, vision loss, difficulty swallowing, etc. Diagnosing cystinosis commonly involves a comprehensive evaluation of characteristic features, blood tests, and physical examination. The healthcare provider may also utilize urinalysis to determine the excess loss of minerals, nutrients, electrolytes and amino acids. Furthermore, tandem mass spectrometry technique might be performed to accurately measure cystine levels in white blood cells. In some cases, genetic testing may be recommended to confirm a diagnosis in patients.
The escalating prevalence of mutations in the CTNS gene, which can lead to a deficiency in the protein cystinosin, resulting in cystine buildup and crystal formation, is primarily driving the cystinosis market. In addition to this, the inflating utilization of cystine-depleting agents, like cysteamine, since they work by interacting with cystine within lysosomes and converting it into a form that can be excreted, thereby effectively lowering cystine levels, is also creating a positive outlook for the market. Moreover, the widespread adoption of renal replacement therapy on account of its several advantages, including restored normal kidney function, improved calcium-phosphate balance, and reduced risk of renal osteodystrophy, is further bolstering the market growth. Apart from this, the rising usage of Nissen fundoplication to help maintain nutrient absorption, improving overall growth and health, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy that aims to replace the faulty CTNS gene with a functional copy, restoring the ability to transport cystine out of lysosomes, is expected to drive the cystinosis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the cystinosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for cystinosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cystinosis market in any manner.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
Competitive Landscape:
This report also provides a detailed analysis of the current cystinosis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Drugs | Company Name |
---|---|
Procysbi (cysteamine bitartrate) | Raptor Pharmaceutical Corporation |
Cystaran (cysteamine ophthalmic solution) | Leadiant Biosciences |
Cystadrops | Recordati Rare Diseases |
NPI-001 | Nacuity Pharmaceuticals |
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
Epidemiology Insights
Cystinosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies